No Data
KEYMED BIO-B (02162.HK) is expected to have a revenue of 0.428 billion yuan in 2024, with a year-on-year growth of 21%.
On March 24, Gelonghui reported that KEYMED BIO-B (02162.HK) announced its annual results for the year ended December 31, 2024, with revenue of RMB 0.428 billion, a year-on-year increase of 21%; gross profit of RMB 0.416 billion, a year-on-year increase of 31%; annual loss of RMB 0.515 billion compared to a loss of RMB 0.357 billion in the same period last year. As of December 31, 2024, the total amount of cash and cash equivalents, time deposits, and bank wealth management products was RMB 2.156 billion.
KEYMED BIO-B (02162) released the 2024 fiscal year results, with a loss attributable to Shareholders of 0.515 billion yuan, an increase of 43.4% year-on-year.
KEYMED BIO-B (02162) announced its annual performance for the year ending December 31, 2024, with revenue of 0.428 billion yuan...
Express News | KeyMed Biosciences FY Revenue RMB 36 Million
KEYMED BIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024; ANDCHANGE OF COMPOSITION OFTHE NOMINATION COMMITTEE
KEYMED BIO-B (02162.HK) plans to hold a Board of Directors meeting on March 24 to approve the annual performance.
On March 12, Gelonghui reported that KEYMED BIO-B (02162.HK) announced that it will hold a Board of Directors meeting on March 24, 2025 (Monday) to consider and approve the company's and its subsidiaries' performance for the year ending December 31, 2024, and its release, as well as to consider the distribution of a final dividend (if any).
KEYMED BIO-B: DATE OF BOARD MEETING
